Advaxis Inc. buy stratec
Summary
This prediction ended on 03.12.18 with a price of €5.55. The BUY prediction by stratec for Advaxis Inc. performed very badly with a performance of -86.69%. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Advaxis Inc. | - | - | - | - |
iShares Core DAX® | -1.414% | 7.218% | 17.151% | 15.732% |
iShares Nasdaq 100 | -2.316% | 4.450% | 18.360% | 30.945% |
iShares Nikkei 225® | -2.756% | 10.071% | 10.704% | 2.733% |
iShares S&P 500 | -1.849% | 4.760% | 19.639% | 34.852% |
Comments by stratec for this prediction
In the thread Advaxis Inc. diskutieren
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 24.01.2018 der Buy-Einschätzung von tamam mit dem Kursziel 10$ zu.
Überschrift: ADXS has very interesting make-or-break potential, caveat emptor!
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
ADXS reports that 8 of 9 patients were progression-free at the 42 months mark. If researchers could reproduce this in a wider patient population, then addition of the Lm-based immunotherapy might represent a new standard of care.